Matias Pedro M, Carrondo Maria Arménia, Coelho Ricardo, Thomaz Monica, Zhao Xiao-Yan, Wegg Anja, Crusius Kerstin, Egner Ursula, Donner Peter
Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Apartado 127, 2780 Oeiras, Portugal.
J Med Chem. 2002 Mar 28;45(7):1439-46. doi: 10.1021/jm011072j.
The crystal structure of a mutant androgen receptor (AR) ligand-binding domain (LBD) in complex with the agonist 9alpha-fluorocortisol has been determined at 1.95 A resolution. This mutant AR contains two mutations (L701H and T877A) and was previously reported as a high-affinity cortisol/cortisone responsive AR (AR(ccr)) isolated from the androgen-independent human prostate cancer cell lines MDA PCa 2a and 2b (Zhao et al. Nature Med. 2000, 6, 703-6). The three-dimensional structure of the AR(ccr) LBD complexed with 9alpha-fluorocortisol shows the typical conformation of an agonist-bound nuclear receptor in which helix 12 is precisely positioned as a "lid" for the ligand-binding pocket. Binding of 9alpha-fluorocortisol to the AR(ccr) involves favorable hydrogen bond patterns on the C17 and C21 substituents of the ligand due to the mutations at 701 and 877 in the AR(ccr). Our studies provide the first structural explanation for the glucocorticoid activation of AR(ccr), which is important for the development of new therapeutic treatments for androgen-independent prostate cancer.
已确定与激动剂9α-氟皮质醇复合的突变雄激素受体(AR)配体结合域(LBD)的晶体结构,分辨率为1.95埃。该突变AR包含两个突变(L701H和T877A),先前被报道为从雄激素非依赖性人前列腺癌细胞系MDA PCa 2a和2b中分离出的高亲和力皮质醇/可的松反应性AR(AR(ccr))(Zhao等人,《自然医学》,2000年,6卷,703 - 706页)。与9α-氟皮质醇复合的AR(ccr) LBD的三维结构显示了激动剂结合的核受体的典型构象,其中螺旋12精确地定位为配体结合口袋的“盖子”。由于AR(ccr)中701和877位点的突变,9α-氟皮质醇与AR(ccr)的结合涉及配体C17和C21取代基上有利的氢键模式。我们的研究为AR(ccr)的糖皮质激素激活提供了首个结构解释,这对于开发雄激素非依赖性前列腺癌的新治疗方法很重要。